Marufa Akter out of New Zealand tour, BCB official says no rush on foot injury

Marufa Akter, rated among Bangladesh's fastest bowlers, will sit out the upcoming white-ball series against New Zealand. The team departs Dhaka on 4 December for a tour featuring three ODIs and three T20Is. A top official attached to the board's women's unit, speaking on condition of anonymity, said Marufa is unavailable for the tour. Notably, that information comes not from an official statement or a squad announcement but from a single unnamed source.

What the injury is

According to the report, bone erosion has been detected at the base of the fifth metatarsal in her right foot. She has been fitted with an Aircast brace and advised four weeks of bed rest. She is expected to resume walking in the first week of December — roughly the same time the team will be boarding its flight from Dhaka. No date has been set for her return to bowling.

In the same official's words: "Marufa is unavailable for the New Zealand tour. There is a risk of the pain recurring and we do not want to rush her. She will be given full time." That statement is the only direct quotation in the entire story, and even it consists of two consecutive remarks from one person — it therefore does not amount to cross-verification.

The Australia link

The report also says Marufa received an injection before the Australia tour, that it did not produce the expected response, and that she did not play the final match of that tour. This portion is the reporter's own sourcing and is not backed by any medical record or board statement. If accurate, it suggests the problem pre-dated the Australia tour and has persisted since.

Timeline

The available details sketch a straightforward sequence: injection before the Australia tour, no expected response, omission from the final match, the start of four weeks of bed rest in early November, an expected return to walking in the first week of December, and the team's departure on 4 December. The sequence is internally consistent, but two significant gaps remain — no year is given for any date, and the date of publication is absent. Without those, it is impossible to judge whether this is an early warning or a retrospective confirmation.

What is not addressed

The biggest question is whether Marufa was in the original squad for the New Zealand tour. Language suggesting she "will miss out" implies she was picked, but this is never made explicit. If she was in the squad, who replaced her? No replacement is named, even though that is the single most important piece of information in a story about a frontline seamer being ruled out. The match dates of the series are also missing, so no possible return window can be calculated. There is no discussion of whether surgery might be required, even though bone erosion, a failed injection and a brace would normally prompt that question. Nor is it stated whether any other player in the squad is carrying an injury.

Medical background (general information, not part of the report)

The base of the fifth metatarsal is considered a watershed zone for blood supply and is the most common site for Jones fractures and stress fractures. Bone heals slowly there and recurrence rates are high — which makes the "no rush" framing medically coherent. Bone erosion typically points to a chronic stress response or an inflammatory process rather than an acute fracture. One point remains doubtful: "four weeks of bed rest" is heavier than usual practice for a metatarsal stress injury, where the standard advice is non-weight-bearing status with a brace. It is more reasonable to read this as offloading rather than strict bed rest unless separately confirmed.

Impact on the team

The report establishes that the team is losing its leading seamer and that the board is prioritising her recovery, but it does not establish how big the blow is. How many overs she has bowled in recent series, how deep Bangladesh's pace reserves are, and what weight this series carries — none of that appears. The story therefore answers "what happened" but not "how bad it is."

What can be checked

The 4 December departure and the series format can be verified against BCB listings. It can also be checked whether Marufa was in the original squad and whether she appears on the scorecard for the final match of the Australia tour — the latter would directly confirm or refute one claim. But the recurrence of pain, the stated intent to avoid a repeat, and the assertion that the injection failed all rest on a single anonymous source and cannot be independently verified.

Assessment

Two things should be kept in mind while reading this story. First, the headline uses cautious language about her being likely to miss out, while the official's quoted words state plainly that she is unavailable — the report's internal evidence is stronger than its headline. Second, every key claim comes from one unnamed official. Any downstream citation should attribute it as "Cricbuzz, quoting an anonymous BCB official," not present it as established fact.

What to watch next

The BCB's official squad announcement; the full series schedule; whether the word "surgery" enters the story; whether she appears in the preliminary list for any subsequent tournament, which will reveal how long "full time" actually turns out to be; and whether local Bangladeshi media corroborate the injection detail.

Bottom line

This is a story whose information density sits almost entirely in medical detail, while the structural facts — squad status, replacement, schedule, return window — are absent. It is publishable as a short report, but it cannot serve as a factual baseline.